Patients with cardiomyopathy and/or LVEF < LLN.
Prior or current cardiomyopathy including but not limited to the following: known hypertrophic cardiomyopathy, known arrhythmogenic right ventricular cardiomyopathy, previous moderate or severe impairment of left ventricular systolic function (left ventricular ejection fraction [LVEF] < 45% on echocardiography or equivalent on multigated acquisition scan [MuGA]) even if full recovery has occurred
Documented cardiomyopathy;
Active cardiomyopathy
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within 3 months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination
Patients with clinically significant cardiomyopathy requiring treatment
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Patients with LVEF =< 40% from treatment with anthracyclines for all malignancies at any dose without evidence of other causes of cardiomyopathy
History of familial cardiomyopathy
History of infiltrative cardiomyopathy or restrictive cardiomyopathy
Transthyretin amyloid (ATTR) cardiomyopathy (CM)
Cardiomyopathy primarily caused by non-amyloid diseases (e.g. ischemic heart disease; valvular heart disease)
Symptomatic cardiomyopathy
Patients with LVEF =< 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy
History of familial cardiomyopathy
History of infiltrative cardiomyopathy or restrictive cardiomyopathy
Documented cardiomyopathy
Documented cardiomyopathy
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Known history of cardiomyopathy
Patients with clinically significant cardiomyopathy requiring treatment
Documented cardiomyopathy
Significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, ejection fraction (EF) =< 40% or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination. Echocardiogram will be performed during screening evaluation
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, ejection fraction (EF) =< 40% or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination; echocardiogram will be performed during screening evaluation
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, ejection fraction (EF) =< 40% or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination; echocardiogram will be performed during screening evaluation
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Prior history of cardiomyopathy.
Uncontrolled hypertension or cardiomyopathy
Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular outflow obstruction
Any grade immune-related pneumonitis, cardiomyopathy, or hepatitis
Have cardiomyopathy
Receiving treatment for cardiomyopathy or heart failure
Uncorrected primary obstructive or severe regurgitative valvular disease:\r\n* Nondilated (restrictive); or\r\n* Hypertrophic cardiomyopathy; or\r\n* Significant systemic ventricular outflow obstruction
Patients with any of the following cardiac conditions:\r\n* Symptomatic restrictive cardiomyopathy\r\n* Dilated cardiomyopathy\r\n* Unstable angina within 4 months prior to enrollment\r\n* New York Heart Association functional class III-IV heart failure on active treatment\r\n* Symptomatic pericardial effusion
History of myocardial disease, such as myocarditis, cardiomyopathy, congestive heart failure, ischemic cardiomyopathy
Pre-existing ischemic heart disease (includes angina if documented in electronic medical record [EMR]) or ongoing cardiomyopathy.
Cirrhosis, cardiomyopathy, restrictive heart disease, or bronzing of the skin
